Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01865799 · ClinicalTrials.gov registry record
A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA
A clinical trial of Pre-exposure Prophylaxis for Prevention of HIV Infection, sponsored by Gilead Sciences.
- Completed
- Registry status
- 64,186
- Enrollment target
- 1
- Study location
NCT01865799: Completed study of Pre-exposure Prophylaxis for Prevention of HIV Infection, sponsored by Gilead Sciences.
NCT01865799 is a study of Pre-exposure Prophylaxis for Prevention of HIV Infection that has completed, run by Gilead Sciences. The registered enrollment target is 64,186 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01865799, a study of Pre-exposure Prophylaxis for Prevention of HIV Infection, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- 64,186 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, 3-year observational study to describe drug utilization in uninfected individuals (UIs) who initiate emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) (Truvada®) for a pre-exposure prophylaxis (PrEP) indication. An electronic source of pharmacy/medical encounter information will be used to assess the demographics and other characteristics of the subjects prescribed FTC/TDF or its components in a prospective fashion. The data provider will supply all the de-identified information regarding each visit/interaction that the subject has had with the health system and all the diagnoses and medications that the UI has had prospectively and retrospectively for the length of time captured by the source selected. 200 physicians who prescribe FTC/TDF for a PrEP indication will be sampled from the same source.
Conditions Studied
Study Locations (1)
California
- Gilead Sciences, Inc. - Foster City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64,186 participants |
| Start Date | 2013-04-22 |
| Est. Completion | 2018-01-22 |
What the finished NCT01865799 record still lists
NCT01865799 is an observational study that tracks outcomes without assigning an intervention. Its 64,186 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Pre-exposure Prophylaxis for Prevention of HIV Infection appearing as the primary indexed condition, and to 0 interventions.
NCT01865799 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01865799 about?
NCT01865799 is a clinical study titled "A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA". This is a prospective, 3-year observational study to describe drug utilization in uninfected individuals (UIs) who initiate emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) (Truvada®) for a pre-exposure prophylaxis (PrEP) indication. An electronic source of pharmacy/medical encounter informa...
What is the current status of trial NCT01865799?
This trial is currently completed. The enrollment target is 64,186 participants. The study started on 2013-04-22. Estimated completion is 2018-01-22.
What conditions does trial NCT01865799 study?
This clinical trial studies the following conditions: Pre-exposure Prophylaxis for Prevention of HIV Infection.
Who is sponsoring clinical trial NCT01865799?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01865799 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04473833 · 65,000 participants · NA
Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer
- NCT05128006 · 63,200 participants
Direct-to-patient Teledermatology and Computer-assisted Diagnosis
- NCT06003192 · 63,000 participants · NA
Screen Smart: Using Digital Health to Improve HIV Screening and Prevention
- NCT05723614 · 61,770 participants · NA
TRUsted rEsidents and Housing Assistance to Decrease Violence Exposure in New Haven
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI